bioartificial

bioartificial

(bī″ō-ăr″tĭ-fĭsh′ăl) [″ + ″]
Composed of both living and manufactured components, typically a collection of cells held within a scaffolding or membrane. Bioartificial organs can be used to assist patients with organ failure (e.g., end-stage heart, kidney, liver, or pancreatic disease).
References in periodicals archive ?
At the same time that bioartificial liver therapy improved outcomes for treated patients, it provided patients with a trend towards additional time for a liver transplant to become available (median of 2 days for all patients).
Industry Overview II-1 Artificial Organs Revolutionize Medical Technology Industry II-1 Current and Future Analysis II-1 Market Outlook II-2 Opportunities Abound for Bioartificial Organs II-2 Bionics to Play Crucial Role II-3 Economic Situation Plays a Pivotal Role in ESRD Treatment Accessibility II-3
OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developing the first-of-its-kind bioartificial liver device intended for the treatment of liver failure, announced today that its proprietary 'PICM-19' liver stem cell line is onboard the Space Shuttle "Endeavour" as part of a scientific experiment to investigate the differentiation and function of stem cells in space.
Humes to combine the benefits of sorbent therapy with the exciting possibilities of the bioartificial kidney," said Peter M.
HepaLife Bolsters Development and Strengthens Its IP Portfolio Through Acquisition of Bioartificial Liver Technology: Clinically Evaluated in over 170 Human Patients, with 12 Additional Patents and Licenses, and FDA's 'Orphan Drug' and 'Fast-Track' Designation
Arbios' products in development include the SEPET(TM) Liver Assist Device, a novel blood purification therapy, and the HepatAssist(TM) Bioartificial Liver System, combining liver cell therapy and blood detoxification.
OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developing the first-of-its-kind bioartificial liver device intended for the treatment of liver failure announced today significant process improvements for cell manufacturing and storage, important factors in cost-efficiently producing enough cell-based liver devices for in-vivo trials, and ultimately, clinical application.
OTCBB: HPLF) (FWB: HL1) (WKN: 500625), today announced the development of two new derivative cell lines from the Company's patented PICM-19 liver stem cells for use in HepaLife's first-of-its-kind bioartificial liver device currently under development for the treatment of human liver failure.
Michael Millis Brings Hospital and Clinical Research Expertise to Company's Bioartificial Liver Treatment
OTCBB:HPLF) (FWB:HL1) (WKN:500625) developing the first-of-its-kind bioartificial liver device intended for the treatment of liver failure, announced today that the Company has completed a Private Placement of its securities consisting of shares and warrants to institutional and accredited investors for aggregate gross proceeds of approximately $4,530,000.
OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that new tests of its bioartificial liver device demonstrate the Company's bioreactor system and patented PICM-19 cells inside the device remain functional over prolonged periods time, far exceeding the number of treatment hours referenced in published research studies of human liver failure patients undergoing conventional liver support therapies.
OB has two innovative, proprietary liver-assist product candidates in clinical development: SEPET(TM), a proprietary system that selectively filters the blood for patients with acute- on-chronic liver failure, currently in a Phase 1/2 feasibility study with positive interim data; and HepatAssist(TM), a unique bioartificial liver system that fully replaces human liver function, in patients with acute liver failure, currently awaiting to re-start Phase 3 clinical development.